,Request: Request Number  ↑,Product,DOC ID,Question,accuracy,extracted_keywords_1,keywords_1,Document_Name_1,DOC_ID_1,new_keywords_1,score_1,extracted_keywords_2,keywords_2,Document_Name_2,DOC_ID_2,new_keywords_2,score_2,extracted_keywords_3,keywords_3,Document_Name_3,DOC_ID_3,new_keywords_3,score_3
0,REQ-29479,Wegovy,SEOB 111,Please email Dr. Luu Sema 2.4mg Overview for his plan’s review. Infographics when available.,not accurate,"{'dr', 'available', 'overview'}","overview,approval,summary",Approval and Product Overview (SEOB 010) (v3.0),SEOB 010,",summary,approval,overview",20.0,"{'dr', 'available', 'overview'}","medicaid,formulary,summary,overview",Wegovy Medicaid Summary (SEOB 400) (v2.0),SEOB 400,",medicaid,summary,formulary,overview",16.6666666667,"{'dr', 'available', 'overview'}","step,overview,slide,clinical,pi",Clinical Overview of Wegovy (SEOB 601) (v1.0),SEOB 601,",step,slide,clinical,pi,overview",14.2857142857
1,REQ-42253,Ozempic,SEM 032,"Provider has a patient with type 2 diabetes who was diagnosed with a benign tumor on the pancreas. She wanted to find out if we have any studies that included patients with the same condition, and is it safe to start them on Ozempic?",not accurate,"{'study', 'tumor', '2', 'type 2', 'ozempic', 'safety', 'diabetes', 'start', 'pancreas', 'type 2 diabetes', 'benign'}","hypoglycemia,hypo,safety",Hypoglycemia (SEM 120) (v9.0),SEM 120,",hypo,hypoglycemia,safety",7.6923076923,"{'study', 'tumor', '2', 'type 2', 'ozempic', 'safety', 'diabetes', 'start', 'pancreas', 'type 2 diabetes', 'benign'}","type 1,diabetes,t1dm,t1d",Type 1 Diabetes (SEM 090) (v12.0),SEM 090,",diabetes,t1dm,t1d,type 1",7.1428571429,"{'study', 'tumor', '2', 'type 2', 'ozempic', 'safety', 'diabetes', 'start', 'pancreas', 'type 2 diabetes', 'benign'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",7.1428571429
2,REQ-43085,Ozempic,SEM 134,Is there any reason you would not want to use Ozempic in a younger patient with Type 2 diabetes due to increased risk of cancer or other long term issues?,accurate with one of docID,"{'2', 'type 2', 'long', 'cancer', 'ozempic', 'longterm', 'long term', 'risk', 'diabetes', 'use', 'type 2 diabetes', 'longest', 'term'}","long-term,longest,duration,longer,time",Long-Term Data (SEM 174) (v5.0),SEM 174,",time,duration,longterm,long-term,longest",12.5,"{'2', 'type 2', 'long', 'cancer', 'ozempic', 'longterm', 'long term', 'risk', 'diabetes', 'use', 'type 2 diabetes', 'longest', 'term'}","neoplasms,cancer,neoplasm",Neoplasms  (SEM 134) (v7.0),SEM 134,",neoplasm,cancer",7.1428571429,"{'2', 'type 2', 'long', 'cancer', 'ozempic', 'longterm', 'long term', 'risk', 'diabetes', 'use', 'type 2 diabetes', 'longest', 'term'}","prevention,cardiovascular,mace,cv,risk,",SUSTAIN 6-Primary vs. Secondary Prevention (SEM 167) (v5.0),SEM 167,",cardiovascular,mace,prevention,risk",6.25
3,REQ-43155,Ozempic,SEM 601,Please email me a copy of the updated Ozempic on label slide deck.,accurate with one of docID,"{'slide', 'deck', 'ozempic'}","clinical,overview,slide,slides,deck",Clinical Overview of Ozempic (SEM 601) (v4.0),SEM 601,",clinical,deck,slide,overview",40.0,"{'slide', 'deck', 'ozempic'}","sustain,overview,slide,slides,clinical",Cover to Ozempic Clinical Overview Deck (SEM 600) (v5.0),SEM 600,",sustain,clinical,slide,overview",16.6666666667,"{'slide', 'deck', 'ozempic'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",16.6666666667
4,,Ozempic,SEM 600,Please email me a copy of the updated Ozempic on label slide deck.,accurate with one of docID,"{'slide', 'deck', 'ozempic'}","clinical,overview,slide,slides,deck",Clinical Overview of Ozempic (SEM 601) (v4.0),SEM 601,",clinical,deck,slide,overview",40.0,"{'slide', 'deck', 'ozempic'}","sustain,overview,slide,slides,clinical",Cover to Ozempic Clinical Overview Deck (SEM 600) (v5.0),SEM 600,",sustain,clinical,slide,overview",16.6666666667,"{'slide', 'deck', 'ozempic'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",16.6666666667
5,REQ-43318,Ozempic,SEM 122,Christina would like to know if there is data on a tapering effect of weight loss seen with OZEMPIC.,not accurate,"{'effect', 'data', 'ozempic', 'weight loss', 'weight'}","mechanism,weight,weight loss",Mechanism of Weight Loss (SEM 141) (v6.0),SEM 141,",weight loss,mechanism,weight",33.3333333333,"{'effect', 'data', 'ozempic', 'weight loss', 'weight'}","weight,victoza",Weight vs. Victoza (SEM 142) (v6.0),SEM 142,",weight,victoza",16.6666666667,"{'effect', 'data', 'ozempic', 'weight loss', 'weight'}","obesity,weight",Obesity Indication (SEM 155) (v13.0),SEM 155,",weight,obesity",16.6666666667
6,REQ-43325,Ozempic,SEM 1000,Is there any data showing Ozempic in use for patients who have neuroendocrine tumors of the GI tract?,not accurate,"{'tumor', 'data', 'ozempic', 'tumors', 'use', 'gi'}","gastrointestinal,gi,management,ae",Management of GI Adverse Events (GLP1 014) (v1.0),GLP1 014,",management,gi,ae",12.5,"{'tumor', 'data', 'ozempic', 'tumors', 'use', 'gi'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",11.1111111111,"{'tumor', 'data', 'ozempic', 'tumors', 'use', 'gi'}","gi,gastrointestinal,safety,ae,adverse events",GI Adverse Events (SEM 005) (v11.0),SEM 005,",ae,gi,safety,adverse event",11.1111111111
7,REQ-43330,Ozempic,SEM 1000,"Dr. Jentner would like to know if the Ozempic pens are bio-degradable or if they can be recycled.  She would like to know if the pen needs/can be disposed of in a sharps container,if it doesn’t  have a needle attached.",not accurate,"{'dr', 'pen', 'ozempic', 'pens'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",14.2857142857,"{'dr', 'pen', 'ozempic', 'pens'}","ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,",fpg,ozempic,preprandial,glucose,fasting,semaglutide",11.1111111111,"{'dr', 'pen', 'ozempic', 'pens'}","pen,device,pen overview,device overview,dosing,volume,dose,flextouch,flexpen",Pen Overview (SEM 028) (v10.0),SEM 028,",pen overview,volume,dose,device,flexpen,pen,device overview,flextouch",9.0909090909
8,REQ-43341,Ozempic,SEM 125,"Can you send me any information on Ozempic’s impact on hypoglycemia, creatinine levels, and/or overall kidney function in patients with CKD stage 4 vs. stage 5?",accurate with one of docID,"{'level', 'overall', 'send', 'function', 'impact', 'creatinine', 'vs', 'hypoglycemia', 'kidney', 'information'}","renal,kidney,outcomes,creatinine,uar,scr,glomerular,gfr",Renal Outcomes (GLP1 012) (v2.0),GLP1 012,",creatinine,scr,outcomes,renal,gfr,kidney,uar,glomerular",12.5,"{'level', 'overall', 'send', 'function', 'impact', 'creatinine', 'vs', 'hypoglycemia', 'kidney', 'information'}","renal,kidney,dialysis,esrd,gfr,egfr,creatinine,clearance,crcl,nephrotic,transplant",Renal Impairment (SEM 125) (v13.0),SEM 125,",creatinine,clearance,nephrotic,dialysis,renal,gfr,kidney,egfr,transplant,crcl,esrd",10.5263157895,"{'level', 'overall', 'send', 'function', 'impact', 'creatinine', 'vs', 'hypoglycemia', 'kidney', 'information'}","hypoglycemia,hypo,safety",Hypoglycemia (SEM 120) (v9.0),SEM 120,",hypo,hypoglycemia,safety",8.3333333333
9,,Ozempic,SEM 126,"Can you send me any information on Ozempic’s impact on hypoglycemia, creatinine levels, and/or overall kidney function in patients with CKD stage 4 vs. stage 5?",not accurate,"{'level', 'overall', 'send', 'function', 'impact', 'creatinine', 'vs', 'hypoglycemia', 'kidney', 'information'}","renal,kidney,outcomes,creatinine,uar,scr,glomerular,gfr",Renal Outcomes (GLP1 012) (v2.0),GLP1 012,",creatinine,scr,outcomes,renal,gfr,kidney,uar,glomerular",12.5,"{'level', 'overall', 'send', 'function', 'impact', 'creatinine', 'vs', 'hypoglycemia', 'kidney', 'information'}","renal,kidney,dialysis,esrd,gfr,egfr,creatinine,clearance,crcl,nephrotic,transplant",Renal Impairment (SEM 125) (v13.0),SEM 125,",creatinine,clearance,nephrotic,dialysis,renal,gfr,kidney,egfr,transplant,crcl,esrd",10.5263157895,"{'level', 'overall', 'send', 'function', 'impact', 'creatinine', 'vs', 'hypoglycemia', 'kidney', 'information'}","hypoglycemia,hypo,safety",Hypoglycemia (SEM 120) (v9.0),SEM 120,",hypo,hypoglycemia,safety",8.3333333333
10,,Ozempic,SEM 120,"Can you send me any information on Ozempic’s impact on hypoglycemia, creatinine levels, and/or overall kidney function in patients with CKD stage 4 vs. stage 5?",accurate with one of docID,"{'level', 'overall', 'send', 'function', 'impact', 'creatinine', 'vs', 'hypoglycemia', 'kidney', 'information'}","renal,kidney,outcomes,creatinine,uar,scr,glomerular,gfr",Renal Outcomes (GLP1 012) (v2.0),GLP1 012,",creatinine,scr,outcomes,renal,gfr,kidney,uar,glomerular",12.5,"{'level', 'overall', 'send', 'function', 'impact', 'creatinine', 'vs', 'hypoglycemia', 'kidney', 'information'}","renal,kidney,dialysis,esrd,gfr,egfr,creatinine,clearance,crcl,nephrotic,transplant",Renal Impairment (SEM 125) (v13.0),SEM 125,",creatinine,clearance,nephrotic,dialysis,renal,gfr,kidney,egfr,transplant,crcl,esrd",10.5263157895,"{'level', 'overall', 'send', 'function', 'impact', 'creatinine', 'vs', 'hypoglycemia', 'kidney', 'information'}","hypoglycemia,hypo,safety",Hypoglycemia (SEM 120) (v9.0),SEM 120,",hypo,hypoglycemia,safety",8.3333333333
11,REQ-43350,Wegovy,none,Would like more information on patients experiencing dramatic weight loss with wegovy.,not accurate,"{'weight', 'weight loss', 'wegovy', 'information'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",14.2857142857,"{'weight', 'weight loss', 'wegovy', 'information'}","surmount,weight,gip,glp-1,glp1,tirzepatide,mounjaro,gip",vs tirzepatide (SEOB 063) (v3.0),SEOB 063,",tirzepatide,mounjaro,gip,weight,glp-1,surmount",11.1111111111,"{'weight', 'weight loss', 'wegovy', 'information'}","mtc,men 2,anti-obesity,glp-1 ras,wegovy,saxenda,aom",MTC (Medullary Thyroid Carcinoma) (GOBS 003) (v1.0),GOBS 003,",anti-obesity,men 2,wegovy,saxenda,aom,mtc,glp-1 ras",10.0
12,REQ-43424,Rybelsus,none,Provider would like to know if he can use Rybelsus on a patient that is allergic phenergan.,not accurate,"{'use', 'rybelsus', 'allergy'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",16.6666666667,"{'use', 'rybelsus', 'allergy'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",14.2857142857,"{'use', 'rybelsus', 'allergy'}","allergic,allergy,hypersensitivity,sensitivity,anaphylaxis,anaphylactic,urticaria,rash,immunogenic,immunogenicity",Allergic Reactions (OSEM 044) (v8.0),OSEM 044,",immunogenic,hypersensitivity,anaphylaxis,anaphylactic,allergy,urticaria,sensitivity,rash",10.0
13,REQ-43498,Ozempic,SEM 125,"Please send info on Ozempic regarding GFR? Is there a GFR where Ozempic should not be used?

Would also like data on Ozempic and CHF.",not accurate,"{'data', 'ozempic', 'send', 'gfr', 'chf'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",12.5,"{'data', 'ozempic', 'send', 'gfr', 'chf'}","heart,failure,hospitalization,chf,hf,nyha,",SUSTAIN 6-Heart Failure (SEM 163) (v7.0),SEM 163,",hf,nyha,heart,hospitalization,chf,failure",10.0,"{'data', 'ozempic', 'send', 'gfr', 'chf'}","ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,",fpg,ozempic,preprandial,glucose,fasting,semaglutide",10.0
14,,Ozempic,SEM 163,"Please send info on Ozempic regarding GFR? Is there a GFR where Ozempic should not be used?

Would also like data on Ozempic and CHF.",accurate with one of docID,"{'data', 'ozempic', 'send', 'gfr', 'chf'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",12.5,"{'data', 'ozempic', 'send', 'gfr', 'chf'}","heart,failure,hospitalization,chf,hf,nyha,",SUSTAIN 6-Heart Failure (SEM 163) (v7.0),SEM 163,",hf,nyha,heart,hospitalization,chf,failure",10.0,"{'data', 'ozempic', 'send', 'gfr', 'chf'}","ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,",fpg,ozempic,preprandial,glucose,fasting,semaglutide",10.0
15,REQ-43539,Wegovy,SEOB 101,"I would normally send an MI request through Veeva but I am currently not setup in the system after moving back to the field. My role is primarily strategic project focused. .. However, I was in Washington DC this week. I was primarily with lobbyists, poli",not accurate,"{'move', 'week', 'send', 'mi', 'request'}","rationale,dosing,dose,qw,week",Rationale for QW Dosing (SEOB 002) (v8.0),SEOB 002,",qw,rationale,week,dose",12.5,"{'move', 'week', 'send', 'mi', 'request'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0,"{'move', 'week', 'send', 'mi', 'request'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",0.0
16,,Wegovy,SEOB 102,"I would normally send an MI request through Veeva but I am currently not setup in the system after moving back to the field. My role is primarily strategic project focused. .. However, I was in Washington DC this week. I was primarily with lobbyists, poli",not accurate,"{'move', 'week', 'send', 'mi', 'request'}","rationale,dosing,dose,qw,week",Rationale for QW Dosing (SEOB 002) (v8.0),SEOB 002,",qw,rationale,week,dose",12.5,"{'move', 'week', 'send', 'mi', 'request'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0,"{'move', 'week', 'send', 'mi', 'request'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",0.0
17,,Wegovy,SEOB 103,"I would normally send an MI request through Veeva but I am currently not setup in the system after moving back to the field. My role is primarily strategic project focused. .. However, I was in Washington DC this week. I was primarily with lobbyists, poli",not accurate,"{'move', 'week', 'send', 'mi', 'request'}","rationale,dosing,dose,qw,week",Rationale for QW Dosing (SEOB 002) (v8.0),SEOB 002,",qw,rationale,week,dose",12.5,"{'move', 'week', 'send', 'mi', 'request'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0,"{'move', 'week', 'send', 'mi', 'request'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",0.0
18,,Wegovy,SEOB 104,"I would normally send an MI request through Veeva but I am currently not setup in the system after moving back to the field. My role is primarily strategic project focused. .. However, I was in Washington DC this week. I was primarily with lobbyists, poli",not accurate,"{'move', 'week', 'send', 'mi', 'request'}","rationale,dosing,dose,qw,week",Rationale for QW Dosing (SEOB 002) (v8.0),SEOB 002,",qw,rationale,week,dose",12.5,"{'move', 'week', 'send', 'mi', 'request'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0,"{'move', 'week', 'send', 'mi', 'request'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",0.0
19,REQ-43546,Ozempic,SEM 007,Any reports of increased myopathy (muscle weakness) with ozempic. People with high ozempic antibody levels any correlation to increased muscle weakness. Any reports of ozempic worsening metabolic myopathy; such as Pompe disease?,accurate with one of docID,"{'level', 'high', 'ozempic', 'antibody'}","antibody,antibodies,immunogenicity",Antibodies (SEM 007) (v8.0),SEM 007,",immunogenic,antibody",20.0,"{'level', 'high', 'ozempic', 'antibody'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",14.2857142857,"{'level', 'high', 'ozempic', 'antibody'}","ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,",fpg,ozempic,preprandial,glucose,fasting,semaglutide",11.1111111111
20,REQ-43551,Ozempic,SEM 178,Can I get a copy of the data that was on a slide presented at last nights at the speaker program? The slide showed the higher that hemoglobin A1c the bigger the drop with Ozempic.  I believe it was breaking out data at different patients with different A1,not accurate,"{'slide', 'data', 'ozempic', 'program', 'a1c', 'hemoglobin', 'hemoglobin a1c', 'last', 'speaker'}","sustain,overview,slide,slides,clinical",Cover to Ozempic Clinical Overview Deck (SEM 600) (v5.0),SEM 600,",sustain,clinical,slide,overview",8.3333333333,"{'slide', 'data', 'ozempic', 'program', 'a1c', 'hemoglobin', 'hemoglobin a1c', 'last', 'speaker'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",8.3333333333,"{'slide', 'data', 'ozempic', 'program', 'a1c', 'hemoglobin', 'hemoglobin a1c', 'last', 'speaker'}","clinical,overview,slide,slides,deck",Clinical Overview of Ozempic (SEM 601) (v4.0),SEM 601,",clinical,deck,slide,overview",8.3333333333
21,REQ-43581,Saxenda,SAX 062,Dr Udell wants to know if her patient is safe to take Saxenda if they have previously had papillary and follicular cancer,not accurate,"{'cancer', 'safety', 'dr', 'papillary', 'follicular'}","neoplasm,safety,neoplasms",Neoplasms (SAX 104) (v3.0),SAX 104,",neoplasm,safety",16.6666666667,"{'cancer', 'safety', 'dr', 'papillary', 'follicular'}","adverse,events,safety",Adverse Events-Clinical Trials (SAX 027) (v6.0),SAX 027,",events,adverse,safety",14.2857142857,"{'cancer', 'safety', 'dr', 'papillary', 'follicular'}","cancer,tumor,oncology,neoplasm,carcinoma,breast",Breast Neoplasms (SAX 010) (v7.0),SAX 010,",tumor,breast,cancer,neoplasm,oncology,carcinoma",10.0
22,,Saxenda,SAX 088,Dr Udell wants to know if her patient is safe to take Saxenda if they have previously had papillary and follicular cancer,not accurate,"{'cancer', 'safety', 'dr', 'papillary', 'follicular'}","neoplasm,safety,neoplasms",Neoplasms (SAX 104) (v3.0),SAX 104,",neoplasm,safety",16.6666666667,"{'cancer', 'safety', 'dr', 'papillary', 'follicular'}","adverse,events,safety",Adverse Events-Clinical Trials (SAX 027) (v6.0),SAX 027,",events,adverse,safety",14.2857142857,"{'cancer', 'safety', 'dr', 'papillary', 'follicular'}","cancer,tumor,oncology,neoplasm,carcinoma,breast",Breast Neoplasms (SAX 010) (v7.0),SAX 010,",tumor,breast,cancer,neoplasm,oncology,carcinoma",10.0
23,REQ-43582,Ozempic,SEM 008,"Provider has a female patient she started on ozempic. The patient took her first injection on Saturday.  On the Thursday after her first injection of ozempic .25mg, she was outside power washing. That day she noticed itchiness and swelling on her palms an",not accurate,"{'swelling', 'injection', 'female', 'ozempic'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",14.2857142857,"{'swelling', 'injection', 'female', 'ozempic'}","ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,",fpg,ozempic,preprandial,glucose,fasting,semaglutide",11.1111111111,"{'swelling', 'injection', 'female', 'ozempic'}","ozempic,semaglutide injection,glycemic,control,0.25,initial,early,switching,initiation,hyperglycemia",Initial Glycemic Control (SEM 021) (v7.0),SEM 021,",hyperglycemia,ozempic,semaglutide injection,glycemic,switching,initiation,initial,0.25,control,early",7.6923076923
24,REQ-43584,Ozempic,SEM 173,"Hello. This provider is interested in how many clicks to get to the 2mg dose.
Thank you",accurate with one of docID,{'click'},"click,clicks,unmarked dosing,pen,marked,unmarked,increment,dosing,dial,dose,doses",Pen-Dosing by Clicks (SEM 173) (v4.0),SEM 173,",unmarked dosing,increment,click,unmarked,dose,dial,marked,pen",12.5,{'click'},excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0,{'click'},"niosh,hazardous",NIOSH Classification (Sema) (SEM 300) (v6.0),SEM 300,",hazardous,niosh",0.0
25,REQ-43590,Rybelsus,none,Can you lower the dose of metformin when you start a patient on Rybelsus?  Is there any data around this question that can be provided?,not accurate,"{'data', 'rybelsus', 'question', 'dose', 'low', 'start', 'metformin'}","exercise,dosing,physical activity",Dosing-Impact of Exercise (OSEM 091) (v6.0),OSEM 091,",physical activity,exercise,dose",11.1111111111,"{'data', 'rybelsus', 'question', 'dose', 'low', 'start', 'metformin'}","3 mg,initiation,starting,starter",3 mg Safety and Efficacy (OSEM 053) (v12.0),OSEM 053,",start,initiation,3 mg",11.1111111111,"{'data', 'rybelsus', 'question', 'dose', 'low', 'start', 'metformin'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",10.0
26,REQ-43598,Ozempic,SEM 125,Ms penson asked for any on going study information with ozempic and the kidneys,not accurate,"{'study', 'ozempic', 'information'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",16.6666666667,"{'study', 'ozempic', 'information'}","ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,",fpg,ozempic,preprandial,glucose,fasting,semaglutide",12.5,"{'study', 'ozempic', 'information'}","ozempic,semaglutide injection,glycemic,control,0.25,initial,early,switching,initiation,hyperglycemia",Initial Glycemic Control (SEM 021) (v7.0),SEM 021,",hyperglycemia,ozempic,semaglutide injection,glycemic,switching,initiation,initial,0.25,control,early",8.3333333333
27,,Ozempic,SEM 126,Ms penson asked for any on going study information with ozempic and the kidneys,not accurate,"{'study', 'ozempic', 'information'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",16.6666666667,"{'study', 'ozempic', 'information'}","ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,",fpg,ozempic,preprandial,glucose,fasting,semaglutide",12.5,"{'study', 'ozempic', 'information'}","ozempic,semaglutide injection,glycemic,control,0.25,initial,early,switching,initiation,hyperglycemia",Initial Glycemic Control (SEM 021) (v7.0),SEM 021,",hyperglycemia,ozempic,semaglutide injection,glycemic,switching,initiation,initial,0.25,control,early",8.3333333333
28,REQ-43599,Saxenda,SEOB 049,What are the recommendations of switching patients from Saxenda to Wegovy.  Which wegovy dose is compatible/COMPARABLE  to Saxenda 3mg dose,not accurate,"{'recommendation', 'compatible', 'switching', 'wegovy', 'dose'}","switching,switch,wegovy,semaglutide",Switching from GLP-1 RAs (SAX 102) (v5.0),SAX 102,",switching,semaglutide,wegovy,switch",28.5714285714,"{'recommendation', 'compatible', 'switching', 'wegovy', 'dose'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",12.5,"{'recommendation', 'compatible', 'switching', 'wegovy', 'dose'}","mtc,men 2,anti-obesity,glp-1 ras,wegovy,saxenda,aom",MTC (Medullary Thyroid Carcinoma) (GOBS 003) (v1.0),GOBS 003,",anti-obesity,men 2,wegovy,saxenda,aom,mtc,glp-1 ras",9.0909090909
29,REQ-43600,Ozempic,SEM 124,How do you transition a patient from Victoza to Ozempic?,not accurate,"{'transition', 'ozempic', 'victoza'}","weight,victoza",Weight vs. Victoza (SEM 142) (v6.0),SEM 142,",weight,victoza",25.0,"{'transition', 'ozempic', 'victoza'}","structure,victoza",Structure vs Victoza  (SEM 129) (v6.0),SEM 129,",structure,victoza",25.0,"{'transition', 'ozempic', 'victoza'}","victoza,liraglutide,sustain 10",vs Victoza (SEM 116) (v11.0),SEM 116,",liraglutide,sustain 10,victoza",20.0
30,REQ-43601,Wegovy,SEOB 105,Customer requested links to Wegovy phase3b STEP trials.,not accurate,"{'trials', 'trial', 'step', 'wegovy'}",step,Media-STEP 1 Video (SEOB 3001) (v1.0),SEOB 3001,",step",25.0,"{'trials', 'trial', 'step', 'wegovy'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",14.2857142857,"{'trials', 'trial', 'step', 'wegovy'}","step,sustain,forte,diabetes,t2d",STEP 2 vs SUSTAIN FORTE (SEOB 057) (v1.0),SEOB 057,",step,forte,t2d,sustain,diabetes",12.5
31,,Wegovy,SEOB 108,Customer requested links to Wegovy phase3b STEP trials.,not accurate,"{'trials', 'trial', 'step', 'wegovy'}",step,Media-STEP 1 Video (SEOB 3001) (v1.0),SEOB 3001,",step",25.0,"{'trials', 'trial', 'step', 'wegovy'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",14.2857142857,"{'trials', 'trial', 'step', 'wegovy'}","step,sustain,forte,diabetes,t2d",STEP 2 vs SUSTAIN FORTE (SEOB 057) (v1.0),SEOB 057,",step,forte,t2d,sustain,diabetes",12.5
32,,Wegovy,SEOB 113,Customer requested links to Wegovy phase3b STEP trials.,not accurate,"{'trials', 'trial', 'step', 'wegovy'}",step,Media-STEP 1 Video (SEOB 3001) (v1.0),SEOB 3001,",step",25.0,"{'trials', 'trial', 'step', 'wegovy'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",14.2857142857,"{'trials', 'trial', 'step', 'wegovy'}","step,sustain,forte,diabetes,t2d",STEP 2 vs SUSTAIN FORTE (SEOB 057) (v1.0),SEOB 057,",step,forte,t2d,sustain,diabetes",12.5
33,REQ-43603,Ozempic,SEM 154,"Dr. Hart wants to know if there are any studies concerning prescribing Rybelsus or Ozempic for patients who have had gastric bypass surgery. If no studies, can you give any information for this type of patient.",accurate with one of docID,"{'study', 'gastric', 'ozempic', 'information', 'rybelsus', 'dr', 'surgery', 'bypass', 'gastric bypass'}","bariatric,gastric,bypass,sleeve,surgery",Bariatric Surgery (SEM 154) (v6.0),SEM 154,",gastric,bariatric,surgery,bypass,sleeve",27.2727272727,"{'study', 'gastric', 'ozempic', 'information', 'rybelsus', 'dr', 'surgery', 'bypass', 'gastric bypass'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",8.3333333333,"{'study', 'gastric', 'ozempic', 'information', 'rybelsus', 'dr', 'surgery', 'bypass', 'gastric bypass'}","surgery,operation,pre-op,npo,procedure,anesthesia",Surgery (SEM 160) (v4.0),SEM 160,",npo,operation,surgery,procedure,anesthesia,pre-op",7.1428571429
34,,Ozempic,OSEM 092,"Dr. Hart wants to know if there are any studies concerning prescribing Rybelsus or Ozempic for patients who have had gastric bypass surgery. If no studies, can you give any information for this type of patient.",not accurate,"{'study', 'gastric', 'ozempic', 'information', 'rybelsus', 'dr', 'surgery', 'bypass', 'gastric bypass'}","bariatric,gastric,bypass,sleeve,surgery",Bariatric Surgery (SEM 154) (v6.0),SEM 154,",gastric,bariatric,surgery,bypass,sleeve",27.2727272727,"{'study', 'gastric', 'ozempic', 'information', 'rybelsus', 'dr', 'surgery', 'bypass', 'gastric bypass'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",8.3333333333,"{'study', 'gastric', 'ozempic', 'information', 'rybelsus', 'dr', 'surgery', 'bypass', 'gastric bypass'}","surgery,operation,pre-op,npo,procedure,anesthesia",Surgery (SEM 160) (v4.0),SEM 160,",npo,operation,surgery,procedure,anesthesia,pre-op",7.1428571429
35,REQ-43605,Ozempic,SEM 125,"Patient with egfr of 12, can I put her on Ozempic?  Patient has type 2.  And on dialysis.",accurate with one of docID,"{'2', 'type 2', 'ozempic', 'dialysis', 'egfr'}","renal,kidney,dialysis,esrd,gfr,egfr,creatinine,clearance,crcl,nephrotic,transplant",Renal Impairment (SEM 125) (v13.0),SEM 125,",creatinine,clearance,nephrotic,dialysis,renal,gfr,kidney,egfr,transplant,crcl,esrd",14.2857142857,"{'2', 'type 2', 'ozempic', 'dialysis', 'egfr'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",12.5,"{'2', 'type 2', 'ozempic', 'dialysis', 'egfr'}","ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,",fpg,ozempic,preprandial,glucose,fasting,semaglutide",10.0
36,REQ-43607,Ozempic,SEM 012,Dr. Nosser wanted information about if a patient who had thyroid cancer and had their thyroid removed was eligible for Ozempic.,accurate with one of docID,"{'cancer', 'ozempic', 'dr', 'thyroid cancer', 'thyroid', 'information'}","thyroid,neoplasms,carcinoma,cancer,thyroid cancer,ptc,papillary thyroid carcinoma,mtc,medullary thyroid carcinoma,men2,men 2,multiple endocrine neoplasia syndrome type 2,neoplasia,follicular thyroid cancer,ftc",Thyroid Neoplasms (SEM 016) (v10.0),SEM 016,",cancer,ptc,men 2,multiple endocrine neoplasia syndrome type 2,men2,neoplasm,mtc,ftc,neoplasia,thyroid cancer,medullary thyroid carcinoma,thyroid,follicular thyroid cancer,papillary thyroid carcinoma,carcinoma",16.6666666667,"{'cancer', 'ozempic', 'dr', 'thyroid cancer', 'thyroid', 'information'}","neoplasms,cancer,neoplasm",Neoplasms  (SEM 134) (v7.0),SEM 134,",neoplasm,cancer",14.2857142857,"{'cancer', 'ozempic', 'dr', 'thyroid cancer', 'thyroid', 'information'}","thyroid cancer,hypothyroidism,hyperthyroidism,goiter,thyroid,nodules,thyroidectomy,ptc,papillary thyroid carcinoma,mtc,medullary thyroid carcinoma,men2,men2,multiple endocrine neoplasia syndrome type 2",Thyroid Conditions (SEM 012) (v5.0),SEM 012,",hypothyroidism,goiter,ptc,multiple endocrine neoplasia syndrome type 2,thyroidectomy,men2,nodules,hyperthyroidism,mtc,thyroid cancer,medullary thyroid carcinoma,thyroid,papillary thyroid carcinoma",11.7647058824
37,REQ-43608,Saxenda,SAX 062,“What if they had thyroid cancer but it is not medullary?,not accurate,"{'thyroid', 'medullary', 'cancer', 'thyroid cancer'}","thyroid,thyroid neoplasms,mtc,men 2,calcitonin",Thyroid Neoplasms (SAX 018) (v1.0),SAX 018,",men 2,calcitonin,mtc,thyroid,thyroid neoplasms",12.5,"{'thyroid', 'medullary', 'cancer', 'thyroid cancer'}","cancer,tumor,oncology,neoplasm,carcinoma,breast",Breast Neoplasms (SAX 010) (v7.0),SAX 010,",tumor,breast,cancer,neoplasm,oncology,carcinoma",11.1111111111,"{'thyroid', 'medullary', 'cancer', 'thyroid cancer'}","pancreas,cancer,pancreatic,tumor,oncology,neoplasm,carcinoma",Pancreatic Cancer (SAX 015) (v7.0),SAX 015,",tumor,cancer,neoplasm,pancreas,pancreatic,oncology,carcinoma",10.0
38,REQ-43610,Wegovy,SEOB 049,"Please e-mail HCP the following Med Info letter:
- SEOB 049 - Switching from Saxenda",not accurate,"{'switching', 'hcp'}","switch,convert,glp-1,glucagon-like peptide-1,glp,conversion,switching,dosing,saxenda,victoza,liraglutide,exenatide,byetta,bydureon,dulaglutide,trulicity,lixisenatide,adlyxin,ozempic,rybelsus",Switching to-from Other GLP-1 RAs (SEOB 121) (v2.0),SEOB 121,",victoza,glp,switching,saxenda,liraglutide,trulicity,dose,convert,dulaglutide,switch,rybelsus,byetta,exenatide,bydureon,glp-1,glucagon-like peptide-1,lixisenatide,ozempic,adlyxin,conversion",4.7619047619,"{'switching', 'hcp'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0,"{'switching', 'hcp'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",0.0
39,REQ-43612,Rybelsus,OSEM 005,All information on Rybelsus cv data and studies,not accurate,"{'study', 'data', 'rybelsus', 'cardiovascular', 'information'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",25.0,"{'study', 'data', 'rybelsus', 'cardiovascular', 'information'}","soul,cardiovascular outcomes,cv,ongoing",Rybelsus and the SOUL Trial (OSEM 139) (v2.0),OSEM 139,",cardiovascular outcomes,cardiovascular,ongoing,soul",12.5,"{'study', 'data', 'rybelsus', 'cardiovascular', 'information'}","cardiovascular,cvot,pioneer 6,p6,pioneer",Media-PIONEER 6 Video (OSEM 3006) (v2.0),OSEM 3006,",cardiovascular,pioneer,pioneer 6,cvot",12.5
40,REQ-43613,Rybelsus,OSEM 069,Any information on Rybelsus and glp1’s and heartburn,not accurate,"{'rybelsus', 'information'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",20.0,"{'rybelsus', 'information'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",16.6666666667,"{'rybelsus', 'information'}","niosh,hazardous",NIOSH Classification (Sema) (SEM 300) (v6.0),SEM 300,",hazardous,niosh",0.0
41,REQ-43615,Wegovy,SEOB 122,Patient started on wegovy .25 now needs the .5 pen which is not available. 1.0 pen is. Is there a way to adjust 1.0 pen to give .5? Or just try to increase to 1.0 Pt says insurance won’t cover ozempic as alternative,not accurate,"{'ozempic', 'wegovy', 'insurance', 'pen', 'cover', 'available'}","ozempic,versus,vs",vs Ozempic (SEOB 026) (v5.0),SEOB 026,",vs,ozempic,versus",12.5,"{'ozempic', 'wegovy', 'insurance', 'pen', 'cover', 'available'}","ozempic,switch,transition",Switching from Ozempic (SEOB 065) (v7.0),SEOB 065,",transition,ozempic,switch",12.5,"{'ozempic', 'wegovy', 'insurance', 'pen', 'cover', 'available'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",11.1111111111
42,REQ-43626,Norditropin,GHC 002,"Please email this info to the pharmacy: If unopened Norditropin® FlexPro® was left at room temperature (up to 77°F), it must be used within 3 weeks from the day it was left out. Unused portion should be discarded. Do not use past expiration date.Dr. OSCAR",accurate with one of docID,"{'3', 'temperature', 'room', 'room temperature', 'past', 'use', 'norditropin'}","amcp,dossier,4 pg,norditropin",Norditropin Medicaid Summary-4 page (GHC 401) (v4.0),GHC 401,",norditropin,4 pg,dossier,amcp",10.0,"{'3', 'temperature', 'room', 'room temperature', 'past', 'use', 'norditropin'}","amcp,summary,dossier,norditropin",Norditropin Medicaid Summary - 1 page (GHC 400) (v4.0),GHC 400,",norditropin,summary,dossier,amcp",10.0,"{'3', 'temperature', 'room', 'room temperature', 'past', 'use', 'norditropin'}","in-use,storage,stability,expiration,fridge,frozen,freeze,heat,hot,refrigerate,refrigeration,refrigerator,stable,store,temp,temperature,unopen,unopened,warm,room,cool,stored",Storage and Stability (GHC 002) (v5.0),GHC 002,",refrigerator,temp,hot,temperature,freeze,warm,room,frozen,unopen,stored,expiration,fridge,heat,store,stable,cool,storage,in-use",8.6956521739
43,REQ-43631,Rybelsus,OSEM 139,Asked to see information from the Rybelsus SOUL trial,accurate with one of docID,"{'rybelsus', 'trial', 'soul', 'information'}","soul,cardiovascular outcomes,cv,ongoing",Rybelsus and the SOUL Trial (OSEM 139) (v2.0),OSEM 139,",cardiovascular outcomes,cardiovascular,ongoing,soul",14.2857142857,"{'rybelsus', 'trial', 'soul', 'information'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",14.2857142857,"{'rybelsus', 'trial', 'soul', 'information'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",12.5
44,REQ-43632,Rybelsus,SEOB 025,Are there any additional trials/data for weight management and Rybelsus used in the diabetes and/or obesity market.  Will Rybelsus have an indication for weight management?,not accurate,"{'data', 'rybelsus', 'trial', 'indication', 'diabetes', 'management', 'weight', 'obesity', 'trials'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",16.6666666667,"{'data', 'rybelsus', 'trial', 'indication', 'diabetes', 'management', 'weight', 'obesity', 'trials'}","gastrointestinal,gi,management,ae",Management of GI Adverse Events (GLP1 014) (v1.0),GLP1 014,",management,gi,ae",9.0909090909,"{'data', 'rybelsus', 'trial', 'indication', 'diabetes', 'management', 'weight', 'obesity', 'trials'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",8.3333333333
45,REQ-43634,Ozempic,SEM 105,Please send SUSTAIN 5 (SEM 105) per conversation on Ozempic add-on to basal insulin,accurate with one of docID,"{'basal insulin', 'insulin', 'ozempic', 'send', 'sustain', 'basal'}","sustain,insulin,basal,glargine,degludec,lantus,tresiba,nph",Cover to SUSTAIN 5 (add on to basal insulin) (SEM 105) (v6.0),SEM 105,",insulin,sustain,nph,glargine,tresiba,basal,lantus,degludec",27.2727272727,"{'basal insulin', 'insulin', 'ozempic', 'send', 'sustain', 'basal'}","basal,insulin,glargine,lantus",vs Basal insulin (SEM 113) (v7.0),SEM 113,",glargine,insulin,lantus,basal",25.0,"{'basal insulin', 'insulin', 'ozempic', 'send', 'sustain', 'basal'}","insulin,combination,glargine,degludec,tresiba,nph,lantus,basal,aspart,mdi,transition-t2d",Combination with Insulin (SEM 121) (v7.0),SEM 121,",insulin,aspart,nph,combination,glargine,tresiba,transition-t2d,basal,lantus,degludec,mdi",13.3333333333
46,REQ-43635,Ozempic,SEM 004,Is there an ongoing study monitoring retinopathy. Were there patients that could not complete the study because of retinopathy.,accurate with one of docID,"{'study', 'monitor', 'retinopathy', 'ongoing'}","retinopathy,eye,drc,diabetic retinopathy complications,diabetic retinopathy,blindness,blind,vitreous hemorrhage,retina,visual,microvascular",Retinopathy (SEM 004) (v16.0),SEM 004,",visual,microvascular,diabetic retinopathy,drc,blindness,blind,vitreous hemorrhage,retinopathy,eye,diabetic retinopathy complications,retina",7.1428571429,"{'study', 'monitor', 'retinopathy', 'ongoing'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0,"{'study', 'monitor', 'retinopathy', 'ongoing'}","niosh,hazardous",NIOSH Classification (Sema) (SEM 300) (v6.0),SEM 300,",hazardous,niosh",0.0
47,REQ-43638,Ozempic,SEM 139,Can Ozempic be used in patients with liver impairment including cirrhosis of the liver?,accurate with one of docID,"{'impairment', 'liver', 'ozempic', 'cirrhosis'}","hepatic,liver,impairment,ast,alt,alanine aminotransferase,aspartate aminotransferase,hepatic enzymes",Hepatic Function and Impairment (SEM 139) (v8.0),SEM 139,",hepatic enzymes,alt,ast,impairment,alanine aminotransferase,liver,aspartate aminotransferase,hepatic",20.0,"{'impairment', 'liver', 'ozempic', 'cirrhosis'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",14.2857142857,"{'impairment', 'liver', 'ozempic', 'cirrhosis'}","ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,",fpg,ozempic,preprandial,glucose,fasting,semaglutide",11.1111111111
48,REQ-43640,Wegovy,SEOB 043,HCP has questions about the use of semaglutide in a patient on dialysis (PD) with a high insulin requirement.  Please send appropriate information if available,not accurate,"{'insulin', 'high', 'send', 'hcp', 'dialysis', 'use', 'pd', 'semaglutide', 'available', 'information'}","t1d,type 1,insulin",Type 1 Diabetes (SEOB 054) (v1.0),SEOB 054,",insulin,t1d,type 1",8.3333333333,"{'insulin', 'high', 'send', 'hcp', 'dialysis', 'use', 'pd', 'semaglutide', 'available', 'information'}","pharmacokinetics,pharmacodynamics,pk,pd",PK-PD (SEOB 076) (v1.0),SEOB 076,",pharmacodynamics,pd,pharmacokinetics",8.3333333333,"{'insulin', 'high', 'send', 'hcp', 'dialysis', 'use', 'pd', 'semaglutide', 'available', 'information'}","hypoglycemia,glucose,sugar,sulfonylurea,insulin,secretagogue",Hypoglycemia (SEOB 022) (v5.0),SEOB 022,",insulin,sugar,glucose,hypoglycemia,sulfonylurea,secretagogue",6.6666666667
49,REQ-43648,Rybelsus,OSEM 112,Physician asking how to administer Rybelsus in a patient who needs to take thyroid medication too.,accurate with one of docID,"{'medication', 'thyroid', 'administer', 'rybelsus'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",14.2857142857,"{'medication', 'thyroid', 'administer', 'rybelsus'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",12.5,"{'medication', 'thyroid', 'administer', 'rybelsus'}","synthroid,thyroid,levothyroxine,t3,t4,tsh",DDI Levothyroxine (OSEM 112) (v15.0),OSEM 112,",t4,levothyroxine,tsh,t3,thyroid,synthroid",11.1111111111
50,REQ-43649,Rybelsus,OSEM 040,How do nausea rates compare between ozempic and rybelsus (please include MI letter OSEM 040 in response,accurate with one of docID,"{'ozempic', 'mi', 'rybelsus', 'response', 'nausea', 'compare'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",25.0,"{'ozempic', 'mi', 'rybelsus', 'response', 'nausea', 'compare'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",22.2222222222,"{'ozempic', 'mi', 'rybelsus', 'response', 'nausea', 'compare'}","ozempic,comparison,semaglutide injection,semaglutide sq,semaglutide sc,semaglutide subcutaneous,semaglutide comparison",vs Ozempic (OSEM 040) (v16.0),OSEM 040,",semaglutide subcutaneous,ozempic,semaglutide injection,semaglutide comparison,compare,semaglutide sc,semaglutide sq",18.1818181818
51,REQ-43650,Saxenda,SEOB 047,This is for saxenda and wegovy - dr wants to know what information we have to share on treating NASH with our products she has a lot of pts with NASH and she has read about GLP-1 use in those pts,not accurate,"{'share', 'dr', 'wegovy', 'use', 'glp-1', 'nash', 'information'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",10.0,"{'share', 'dr', 'wegovy', 'use', 'glp-1', 'nash', 'information'}","summary,overview,information,monograph",Product Overview (SAX 025) (v7.0),SAX 025,",information,summary,overview,monograph",10.0,"{'share', 'dr', 'wegovy', 'use', 'glp-1', 'nash', 'information'}","switching,switch,wegovy,semaglutide",Switching from GLP-1 RAs (SAX 102) (v5.0),SAX 102,",switching,semaglutide,wegovy,switch",10.0
52,,Saxenda,SAX 042,This is for saxenda and wegovy - dr wants to know what information we have to share on treating NASH with our products she has a lot of pts with NASH and she has read about GLP-1 use in those pts,not accurate,"{'share', 'dr', 'wegovy', 'use', 'glp-1', 'nash', 'information'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",10.0,"{'share', 'dr', 'wegovy', 'use', 'glp-1', 'nash', 'information'}","summary,overview,information,monograph",Product Overview (SAX 025) (v7.0),SAX 025,",information,summary,overview,monograph",10.0,"{'share', 'dr', 'wegovy', 'use', 'glp-1', 'nash', 'information'}","switching,switch,wegovy,semaglutide",Switching from GLP-1 RAs (SAX 102) (v5.0),SAX 102,",switching,semaglutide,wegovy,switch",10.0
53,REQ-43651,Wegovy,SAX 012,"What are the long term side effects of chronic GLP1RA use, specifically on the pancreas/metabolically?",not accurate,"{'long', 'longterm', 'long term', 'glp1-ra', 'pancreas', 'chronic', 'use', 'longest', 'term'}","long-term,longest,duration,longer,long,step 5",Long-Term Data (SEOB 088) (v3.0),SEOB 088,",long,step 5,duration,longterm,long-term,longest",25.0,"{'long', 'longterm', 'long term', 'glp1-ra', 'pancreas', 'chronic', 'use', 'longest', 'term'}","step 5,long term,2 year,104 weeks,sustained",Cover to STEP 5 (SEOB 105) (v2.0),SEOB 105,",sustained,step 5,longterm,long term,2 year,104 weeks",15.3846153846,"{'long', 'longterm', 'long term', 'glp1-ra', 'pancreas', 'chronic', 'use', 'longest', 'term'}","cancer,neoplasm,pancreas,pancreatic",Pancreatic Cancer (SEOB 021) (v4.0),SEOB 021,",neoplasm,cancer,pancreas,pancreatic",8.3333333333
54,,Wegovy,SAX 013,"What are the long term side effects of chronic GLP1RA use, specifically on the pancreas/metabolically?",not accurate,"{'long', 'longterm', 'long term', 'glp1-ra', 'pancreas', 'chronic', 'use', 'longest', 'term'}","long-term,longest,duration,longer,long,step 5",Long-Term Data (SEOB 088) (v3.0),SEOB 088,",long,step 5,duration,longterm,long-term,longest",25.0,"{'long', 'longterm', 'long term', 'glp1-ra', 'pancreas', 'chronic', 'use', 'longest', 'term'}","step 5,long term,2 year,104 weeks,sustained",Cover to STEP 5 (SEOB 105) (v2.0),SEOB 105,",sustained,step 5,longterm,long term,2 year,104 weeks",15.3846153846,"{'long', 'longterm', 'long term', 'glp1-ra', 'pancreas', 'chronic', 'use', 'longest', 'term'}","cancer,neoplasm,pancreas,pancreatic",Pancreatic Cancer (SEOB 021) (v4.0),SEOB 021,",neoplasm,cancer,pancreas,pancreatic",8.3333333333
55,REQ-43652,Ozempic,SEM 091,Are there any studies using Ozempic with Type1 and Type 1.5 Diabetics?,not accurate,"{'study', 'ozempic', 'type 1'}","type 1 diabetes mellitus,type 1 diabetes,type 1,t1d,t1dm",Type 1 Diabetes (GLP1 008) (v3.0),GLP1 008,",t1dm,t1d,type 1",20.0,"{'study', 'ozempic', 'type 1'}","type 1,diabetes,t1dm,t1d",Type 1 Diabetes (SEM 090) (v12.0),SEM 090,",diabetes,t1dm,t1d,type 1",16.6666666667,"{'study', 'ozempic', 'type 1'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",16.6666666667
56,,Ozempic,SEM 090,Are there any studies using Ozempic with Type1 and Type 1.5 Diabetics?,accurate with one of docID,"{'study', 'ozempic', 'type 1'}","type 1 diabetes mellitus,type 1 diabetes,type 1,t1d,t1dm",Type 1 Diabetes (GLP1 008) (v3.0),GLP1 008,",t1dm,t1d,type 1",20.0,"{'study', 'ozempic', 'type 1'}","type 1,diabetes,t1dm,t1d",Type 1 Diabetes (SEM 090) (v12.0),SEM 090,",diabetes,t1dm,t1d,type 1",16.6666666667,"{'study', 'ozempic', 'type 1'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",16.6666666667
57,REQ-43654,Wegovy,SAX 051,This is for saxenda and wegovy - dr is asking for what is the long term data for both saxenda and wegovy as far as pts maintaining therapy and what is the results of patients coming off therapy and how much weight did those pts regain once coming off ther,not accurate,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}","long-term,longest,duration,longer,long,step 5",Long-Term Data (SEOB 088) (v3.0),SEOB 088,",long,step 5,duration,longterm,long-term,longest",21.4285714286,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}","step 5,long term,2 year,104 weeks,sustained",Cover to STEP 5 (SEOB 105) (v2.0),SEOB 105,",sustained,step 5,longterm,long term,2 year,104 weeks",13.3333333333,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",7.1428571429
58,,Wegovy,SEOB 042,This is for saxenda and wegovy - dr is asking for what is the long term data for both saxenda and wegovy as far as pts maintaining therapy and what is the results of patients coming off therapy and how much weight did those pts regain once coming off ther,not accurate,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}","long-term,longest,duration,longer,long,step 5",Long-Term Data (SEOB 088) (v3.0),SEOB 088,",long,step 5,duration,longterm,long-term,longest",21.4285714286,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}","step 5,long term,2 year,104 weeks,sustained",Cover to STEP 5 (SEOB 105) (v2.0),SEOB 105,",sustained,step 5,longterm,long term,2 year,104 weeks",13.3333333333,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",7.1428571429
59,,Wegovy,SEOB 088,This is for saxenda and wegovy - dr is asking for what is the long term data for both saxenda and wegovy as far as pts maintaining therapy and what is the results of patients coming off therapy and how much weight did those pts regain once coming off ther,accurate with one of docID,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}","long-term,longest,duration,longer,long,step 5",Long-Term Data (SEOB 088) (v3.0),SEOB 088,",long,step 5,duration,longterm,long-term,longest",21.4285714286,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}","step 5,long term,2 year,104 weeks,sustained",Cover to STEP 5 (SEOB 105) (v2.0),SEOB 105,",sustained,step 5,longterm,long term,2 year,104 weeks",13.3333333333,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",7.1428571429
60,REQ-43655,Saxenda,SAX 047,What is the pediatric data for Saxenda? Would like to see studies,accurate with one of docID,"{'study', 'pediatric', 'data'}","pediatrics,teens,adolescents,children,pediatric",Pediatrics (SAX 047) (v9.0),SAX 047,",pediatric,adolescent,pediatrics,children,teens",14.2857142857,"{'study', 'pediatric', 'data'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0,"{'study', 'pediatric', 'data'}","niosh,hazardous",NIOSH Classification (Lira) (GLP1 300) (v6.0),GLP1 300,",hazardous,niosh",0.0
61,REQ-43658,Ozempic,SEM 105,"Is there data that can be emailed to help support prescribing Ozempic for a patient with type 2 diabetes where the patient had an inadequate A1C response with Metformin and insulin. Also, the patient has a family history of cardiovascular disease.",not accurate,"{'insulin', '2', 'type 2', 'data', 'ozempic', 'a1c', 'cardiovascular', 'cvd', 'response', 'diabetes', 'type 2 diabetes', 'metformin'}","cardiovascular,outcomes,cvd,cv,ascvd",CV Outcomes (SEM 114) (v7.0),SEM 114,",ascvd,cardiovascular,cvd,outcomes",14.2857142857,"{'insulin', '2', 'type 2', 'data', 'ozempic', 'a1c', 'cardiovascular', 'cvd', 'response', 'diabetes', 'type 2 diabetes', 'metformin'}","kapitza,beta,insulin,response",Cover to Kapitza et al. (Insulin Response) (SEM 151) (v5.0),SEM 151,",beta,insulin,kapitza,response",14.2857142857,"{'insulin', '2', 'type 2', 'data', 'ozempic', 'a1c', 'cardiovascular', 'cvd', 'response', 'diabetes', 'type 2 diabetes', 'metformin'}","verma,cv,cardiovascular,cvd,established cvd,cv risk factors,cvot,rewind",Cover to Verma et al (REWIND CVD Post-hoc Analysis) (OSEM 084) (v4.0),OSEM 084,",cvot,cardiovascular,cvd,established cvd,cv risk factors,rewind,verma",11.7647058824
62,,Ozempic,SEM 106,"Is there data that can be emailed to help support prescribing Ozempic for a patient with type 2 diabetes where the patient had an inadequate A1C response with Metformin and insulin. Also, the patient has a family history of cardiovascular disease.",not accurate,"{'insulin', '2', 'type 2', 'data', 'ozempic', 'a1c', 'cardiovascular', 'cvd', 'response', 'diabetes', 'type 2 diabetes', 'metformin'}","cardiovascular,outcomes,cvd,cv,ascvd",CV Outcomes (SEM 114) (v7.0),SEM 114,",ascvd,cardiovascular,cvd,outcomes",14.2857142857,"{'insulin', '2', 'type 2', 'data', 'ozempic', 'a1c', 'cardiovascular', 'cvd', 'response', 'diabetes', 'type 2 diabetes', 'metformin'}","kapitza,beta,insulin,response",Cover to Kapitza et al. (Insulin Response) (SEM 151) (v5.0),SEM 151,",beta,insulin,kapitza,response",14.2857142857,"{'insulin', '2', 'type 2', 'data', 'ozempic', 'a1c', 'cardiovascular', 'cvd', 'response', 'diabetes', 'type 2 diabetes', 'metformin'}","verma,cv,cardiovascular,cvd,established cvd,cv risk factors,cvot,rewind",Cover to Verma et al (REWIND CVD Post-hoc Analysis) (OSEM 084) (v4.0),OSEM 084,",cvot,cardiovascular,cvd,established cvd,cv risk factors,rewind,verma",11.7647058824
63,REQ-43659,Ozempic,SEM 124,"Dr Castaneda would like more information on converting a patient from Rybelsus to Ozempic? Is these a dose equivalency when switching a patient from a maintenance dose (7 or 14mg)  of Rybelsus to Ozempic (.25, .5, or 1mg)?",not accurate,"{'ozempic', 'rybelsus', 'switching', 'maintenance', '7', 'dr', 'dose', 'information'}","ozempic,semaglutide injection,glycemic,control,0.25,initial,early,switching,initiation,hyperglycemia",Initial Glycemic Control (SEM 021) (v7.0),SEM 021,",hyperglycemia,ozempic,semaglutide injection,glycemic,switching,initiation,initial,0.25,control,early",12.5,"{'ozempic', 'rybelsus', 'switching', 'maintenance', '7', 'dr', 'dose', 'information'}","missed,change,missed,dose,dosing",Dosing-Missed Dose (SEM 011) (v7.0),SEM 011,",missed,change,dose",10.0,"{'ozempic', 'rybelsus', 'switching', 'maintenance', '7', 'dr', 'dose', 'information'}","dosing,guidelines,guideline,missed dose",Dosing-Guidelines (SEM 017) (v6.0),SEM 017,",missed dose,guideline,guidelines,dose",9.0909090909
64,REQ-43661,Saxenda,SEOB 009,"What is Novo currently studying for pediatric patients living with obesity or experiencing weight gain? Provider sees a need, especially with adolescents on antipsychotic medications.",not accurate,"{'pediatric', 'adolescent', 'medications', 'medication', 'weight', 'obesity'}","pediatrics,teens,adolescents,children,pediatric",Pediatrics (SAX 047) (v9.0),SAX 047,",pediatric,adolescent,pediatrics,children,teens",22.2222222222,"{'pediatric', 'adolescent', 'medications', 'medication', 'weight', 'obesity'}","adolescent,adolescents,teens",Adolescents with Obesity (SCALE TEENS) (SAX 103) (v2.0),SAX 103,",teens,adolescent",14.2857142857,"{'pediatric', 'adolescent', 'medications', 'medication', 'weight', 'obesity'}","efficacy,weight,",Weight (SAX 004) (v6.0),SAX 004,",efficacy,weight",14.2857142857
65,REQ-43662,Saxenda,SAX 061,Inquiry Text: This is for saxenda and wegovy - dr is asking for what is the long term data for both saxenda and wegovy as far as pts maintaining therapy and what is the results of patients coming off therapy and how much weight did those pts regain once c,not accurate,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}",regain,Weight Regain After Discontinuation (SAX 051) (v5.0),SAX 051,",regain",9.0909090909,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}","efficacy,weight,",Weight (SAX 004) (v6.0),SAX 004,",efficacy,weight",8.3333333333,"{'data', 'long', 'regain', 'longterm', 'dr', 'wegovy', 'therapy', 'long term', 'weight', 'longest', 'term'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",7.1428571429
66,REQ-43671,Rybelsus,OSEM 021,Doctor requested any additional information on whether Rybelsus is safe in patients with diminished egfr of less then 30.,not accurate,"{'egfr', 'rybelsus', 'information', 'safety'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",33.3333333333,"{'egfr', 'rybelsus', 'information', 'safety'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",12.5,"{'egfr', 'rybelsus', 'information', 'safety'}","glp-1 ra,glucagon-like peptide,safety,hypoglycemia,gastrointestinal,glutide,exenatide,victoza,trulicity,byetta,bydureon,ozempic,adlyxin",Safety vs Other GLP-1 RAs (OSEM 086) (v5.0),OSEM 086,",ozempic,victoza,safety,byetta,exenatide,glp-1 ra,glucagon-like peptide,bydureon,glutide,adlyxin,trulicity,hypoglycemia,gi",6.25
67,REQ-43672,Ozempic,SEM 004,HCP would like more information and data within clinical trials regarding diabetic retinopathy with Ozempic,accurate with one of docID,"{'data', 'clinical', 'ozempic', 'trial', 'retinopathy', 'diabetic retinopathy', 'hcp', 'diabetic', 'trials', 'information'}","sustain,phase,trials,trial,clinical,overview",SUSTAIN Overview (All Phase 3) (SEM 111) (v10.0),SEM 111,",clinical,phase,trial,sustain,overview,trials",23.0769230769,"{'data', 'clinical', 'ozempic', 'trial', 'retinopathy', 'diabetic retinopathy', 'hcp', 'diabetic', 'trials', 'information'}","retinopathy,eye,drc,diabetic retinopathy complications,diabetic retinopathy,blindness,blind,vitreous hemorrhage,retina,visual,microvascular",Retinopathy (SEM 004) (v16.0),SEM 004,",visual,microvascular,diabetic retinopathy,drc,blindness,blind,vitreous hemorrhage,retinopathy,eye,diabetic retinopathy complications,retina",10.5263157895,"{'data', 'clinical', 'ozempic', 'trial', 'retinopathy', 'diabetic retinopathy', 'hcp', 'diabetic', 'trials', 'information'}","sustain,overview,slide,slides,clinical",Cover to Ozempic Clinical Overview Deck (SEM 600) (v5.0),SEM 600,",sustain,clinical,slide,overview",7.6923076923
68,REQ-43680,Ozempic,SEM 164,How does the MOA of Ozempic create a CV benefit? She has looked at the studies and can see how an SGL2 creates a CV benefit but doesn’t understand how Ozempic does.,not accurate,"{'study', 'ozempic', 'cardiovascular', 'cv benefit', 'moa'}","cv,cardiovascular",SUSTAIN 6-CV Outcomes in Subgroup of Patients with CV Risk Factors (SEM 165) (v3.0),SEM 165,",cardiovascular",20.0,"{'study', 'ozempic', 'cardiovascular', 'cv benefit', 'moa'}","cardiovascular,indication,cv",CV Indication (SEM 153) (v6.0),SEM 153,",indication,cardiovascular",16.6666666667,"{'study', 'ozempic', 'cardiovascular', 'cv benefit', 'moa'}","cv,cv indication,cv risk reduction,cardiovascular",Rationale for CV Indication (SEM 162) (v3.0),SEM 162,",cardiovascular,cv indication,cv risk reduction",14.2857142857
69,REQ-43682,Ozempic,SEM 027,Pharm D asked if we have any data for Ozempic being used with patients with kidney transplant? Looking for safety and efficiency data if we have any.,accurate with one of docID,"{'data', 'ozempic', 'safety', 'kidney transplant', 'transplant', 'kidney'}","transplant,solid organ transplant,kidney transplant,liver transplant",Transplant (SEM 027) (v5.0),SEM 027,",transplant,liver transplant,solid organ transplant,kidney transplant",25.0,"{'data', 'ozempic', 'safety', 'kidney transplant', 'transplant', 'kidney'}","renal,kidney,dialysis,esrd,gfr,egfr,creatinine,clearance,crcl,nephrotic,transplant",Renal Impairment (SEM 125) (v13.0),SEM 125,",creatinine,clearance,nephrotic,dialysis,renal,gfr,kidney,egfr,transplant,crcl,esrd",13.3333333333,"{'data', 'ozempic', 'safety', 'kidney transplant', 'transplant', 'kidney'}","hypoglycemia,hypo,safety",Hypoglycemia (SEM 120) (v9.0),SEM 120,",hypo,hypoglycemia,safety",12.5
70,REQ-43683,General-Obesity,SEOB 069,"Provider wants to know if novo needles contain nickel for patient that has nickel allergy 

Also, wants information on GLP-1 and gastroparesis in the setting of post gastric bypass in the setting of weight regain",not accurate,,,,,,,,,,,,,,,,,,
71,,General-Obesity,SAX 054,"Provider wants to know if novo needles contain nickel for patient that has nickel allergy 

Also, wants information on GLP-1 and gastroparesis in the setting of post gastric bypass in the setting of weight regain",not accurate,,,,,,,,,,,,,,,,,,
72,,General-Obesity,SAX 090,"Provider wants to know if novo needles contain nickel for patient that has nickel allergy 

Also, wants information on GLP-1 and gastroparesis in the setting of post gastric bypass in the setting of weight regain",not accurate,,,,,,,,,,,,,,,,,,
73,REQ-43684,Rybelsus,OSEM 120,Provider requested information on  Rybelsus  and the cardio benefits it may offer in the geriatric patients population.  Also were there any additional side effects seen in the geriatric population vs the younger population.,not accurate,"{'vs', 'information', 'rybelsus', 'geriatric'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",14.2857142857,"{'vs', 'information', 'rybelsus', 'geriatric'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",12.5,"{'vs', 'information', 'rybelsus', 'geriatric'}","niosh,hazardous",NIOSH Classification (Sema) (SEM 300) (v6.0),SEM 300,",hazardous,niosh",0.0
74,REQ-43685,Ozempic,SEM 125,Physician is wanting information on using Ozempic in a patient on dialysis.,not accurate,"{'dialysis', 'ozempic', 'information'}","ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,",interaction,drug,semaglutide injection,ozempic",16.6666666667,"{'dialysis', 'ozempic', 'information'}","ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,",fpg,ozempic,preprandial,glucose,fasting,semaglutide",12.5,"{'dialysis', 'ozempic', 'information'}","ozempic,semaglutide injection,glycemic,control,0.25,initial,early,switching,initiation,hyperglycemia",Initial Glycemic Control (SEM 021) (v7.0),SEM 021,",hyperglycemia,ozempic,semaglutide injection,glycemic,switching,initiation,initial,0.25,control,early",8.3333333333
75,REQ-43686,Wegovy,SEOB 026,Please provide clinical differences between Ozempic and Wygovy,accurate with one of docID,"{'difference', 'clinical', 'ozempic'}","ozempic,versus,vs",vs Ozempic (SEOB 026) (v5.0),SEOB 026,",vs,ozempic,versus",20.0,"{'difference', 'clinical', 'ozempic'}","ozempic,switch,transition",Switching from Ozempic (SEOB 065) (v7.0),SEOB 065,",transition,ozempic,switch",20.0,"{'difference', 'clinical', 'ozempic'}","2 mg,2.0 mg,ozempic,sustain forte",vs Ozempic 2 mg (SEOB 008) (v6.0),SEOB 008,",2 mg,sustain forte,ozempic,2.0 mg",16.6666666667
76,REQ-43687,General,OSEM 137,"Please e-mail the following letters to HCP:
- Pipeline (GEN 090)
- Alzheimer's Disease (OSEM 137)

Many thanks,
Chuck Berds",not accurate,"{'pipeline', 'hcp'}",pipeline,Pipeline (GEN 090) (v6.0),GEN 090,",pipeline",50.0,"{'pipeline', 'hcp'}","hcp,additional information required,credentials,clarification,clarify,information",HCP Additional Information Required (GEN 130) (v2.0),GEN 130,",clarification,credentials,hcp,additional information required,information,clarify",14.2857142857,"{'pipeline', 'hcp'}","product information,pi,package insert",PI Discussion (Verbal Response Only) (GEN 1001) (v2.0),GEN 1001,",package insert,product information,pi",0.0
77,,General,GEN 090,"Please e-mail the following letters to HCP:
- Pipeline (GEN 090)
- Alzheimer's Disease (OSEM 137)

Many thanks,
Chuck Berds",accurate with one of docID,"{'pipeline', 'hcp'}",pipeline,Pipeline (GEN 090) (v6.0),GEN 090,",pipeline",50.0,"{'pipeline', 'hcp'}","hcp,additional information required,credentials,clarification,clarify,information",HCP Additional Information Required (GEN 130) (v2.0),GEN 130,",clarification,credentials,hcp,additional information required,information,clarify",14.2857142857,"{'pipeline', 'hcp'}","product information,pi,package insert",PI Discussion (Verbal Response Only) (GEN 1001) (v2.0),GEN 1001,",package insert,product information,pi",0.0
78,REQ-43691,Saxenda,SAX 093,"Please e-mail HCP with the following information:
- Binge Eating Disorder (SAX 093)

HCP also requesting publication:
1. Robert SA, Rohana AG, Shah SA, et al. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with l",accurate with one of docID,"{'3', 'treatment', 'obese', 'hcp', 'bed', 'disorder', 'information'}","binge eating disorder,binge eating,bed,bulimia",Binge Eating Disorder (SAX 093) (v7.0),SAX 093,",bed,bulimia",12.5,"{'3', 'treatment', 'obese', 'hcp', 'bed', 'disorder', 'information'}","summary,overview,information,monograph",Product Overview (SAX 025) (v7.0),SAX 025,",information,summary,overview,monograph",10.0,"{'3', 'treatment', 'obese', 'hcp', 'bed', 'disorder', 'information'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0
79,REQ-43692,Wegovy,SEOB 072,"Please e-mail the following letter to HCP:
- Pregnancy (SEOB 072)",accurate with one of docID,"{'hcp', 'pregnancy'}","pregnancy,pregnant,breastfeed,breastfed,lactation,fertility,fertile,teratogenicity,fetal,fetus,contraception,contraceptive",Pregnancy (SEOB 072) (v2.0),SEOB 072,",contraception,fertile,pregnant,breastfeeding,lactation,teratogenicity,fetus,pregnancy,fetal",10.0,"{'hcp', 'pregnancy'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0,"{'hcp', 'pregnancy'}","bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,",saxenda,anti-obesity medications,wegovy,bariatric surgery",0.0
80,REQ-43701,Rybelsus,OSEM 092,Doctor would like to receive information related to the efficacy of Rybelsus in patients with gastric bypass as it relates to possible interference with its absorption mechanism,not accurate,"{'gastric', 'mechanism', 'information', 'rybelsus', 'efficacy', 'bypass', 'absorption', 'gastric bypass'}","moa,absorption,mechanism,snac,bioavailability",Media-Mechanism of Absorption (OSEM 3011) (v2.0),OSEM 3011,",mechanism,snac,moa,absorption,bioavailability",18.1818181818,"{'gastric', 'mechanism', 'information', 'rybelsus', 'efficacy', 'bypass', 'absorption', 'gastric bypass'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",9.0909090909,"{'gastric', 'mechanism', 'information', 'rybelsus', 'efficacy', 'bypass', 'absorption', 'gastric bypass'}","moa,action,mechanism,insulin,glucagon",Media-Mechanism of Action (OSEM 3012) (v2.0),OSEM 3012,",insulin,mechanism,glucagon,moa,action",8.3333333333
81,REQ-43702,Rybelsus,SEOB 025,Doctor would like to receive any information related to possible weight loss indication for oral semaglutide in the future.,accurate with one of docID,"{'weight loss', 'indication', 'weight', 'oral', 'semaglutide', 'information'}","weight,pound,kilogram,mechanism,weight loss",Mechanism of Weight Loss (OSEM 082) (v3.0),OSEM 082,",pound,mechanism,kilogram,weight loss,weight",22.2222222222,"{'weight loss', 'indication', 'weight', 'oral', 'semaglutide', 'information'}","oral,tablet,oasis,formulation",Oral Formulation (SEOB 025) (v5.0),SEOB 025,",oral,formulation,oasis,tablet",11.1111111111,"{'weight loss', 'indication', 'weight', 'oral', 'semaglutide', 'information'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",10.0
82,REQ-43705,Ozempic,SEM 004,"Please send MI letter. On Ozempic and Diabetes retinopathy along with:
S Feldman et al, early worsening of diabetes retinopathy….(diabetes and metabolism, 44 (2018)
Bain et al, Worsening of diabetic retinopathy with rapid improvement in systemic glucose c",accurate with one of docID,"{'ozempic', 'mi', 'send', 'metabolism', 'diabetic retinopathy', 'diabetes', 'glucose', 'diabetic', 'retinopathy', 'rapid', 'early'}","ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,",fpg,ozempic,preprandial,glucose,fasting,semaglutide",13.3333333333,"{'ozempic', 'mi', 'send', 'metabolism', 'diabetic retinopathy', 'diabetes', 'glucose', 'diabetic', 'retinopathy', 'rapid', 'early'}","ozempic,semaglutide injection,glycemic,control,0.25,initial,early,switching,initiation,hyperglycemia",Initial Glycemic Control (SEM 021) (v7.0),SEM 021,",hyperglycemia,ozempic,semaglutide injection,glycemic,switching,initiation,initial,0.25,control,early",10.5263157895,"{'ozempic', 'mi', 'send', 'metabolism', 'diabetic retinopathy', 'diabetes', 'glucose', 'diabetic', 'retinopathy', 'rapid', 'early'}","retinopathy,eye,drc,diabetic retinopathy complications,diabetic retinopathy,blindness,blind,vitreous hemorrhage,retina,visual,microvascular",Retinopathy (SEM 004) (v16.0),SEM 004,",visual,microvascular,diabetic retinopathy,drc,blindness,blind,vitreous hemorrhage,retinopathy,eye,diabetic retinopathy complications,retina",10.0
83,REQ-43709,Ozempic,SEM 174,What is the long-term data on weight loss for patients taking Ozempic?,not accurate,"{'data', 'ozempic', 'longterm', 'weight loss', 'weight'}","mechanism,weight,weight loss",Mechanism of Weight Loss (SEM 141) (v6.0),SEM 141,",weight loss,mechanism,weight",33.3333333333,"{'data', 'ozempic', 'longterm', 'weight loss', 'weight'}","weight,victoza",Weight vs. Victoza (SEM 142) (v6.0),SEM 142,",weight,victoza",16.6666666667,"{'data', 'ozempic', 'longterm', 'weight loss', 'weight'}","obesity,weight",Obesity Indication (SEM 155) (v13.0),SEM 155,",weight,obesity",16.6666666667
84,REQ-43719,Saxenda,SAX 062,Is Saxenda contraindicated with a personal history of follicular thyroid cancer?,not accurate,"{'cancer', 'contraindication', 'follicular', 'thyroid cancer', 'thyroid', 'follicular thyroid cancer'}","thyroid,thyroid neoplasms,mtc,men 2,calcitonin",Thyroid Neoplasms (SAX 018) (v1.0),SAX 018,",men 2,calcitonin,mtc,thyroid,thyroid neoplasms",10.0,"{'cancer', 'contraindication', 'follicular', 'thyroid cancer', 'thyroid', 'follicular thyroid cancer'}","cancer,tumor,oncology,neoplasm,carcinoma,breast",Breast Neoplasms (SAX 010) (v7.0),SAX 010,",tumor,breast,cancer,neoplasm,oncology,carcinoma",9.0909090909,"{'cancer', 'contraindication', 'follicular', 'thyroid cancer', 'thyroid', 'follicular thyroid cancer'}","pancreas,cancer,pancreatic,tumor,oncology,neoplasm,carcinoma",Pancreatic Cancer (SAX 015) (v7.0),SAX 015,",tumor,cancer,neoplasm,pancreas,pancreatic,oncology,carcinoma",8.3333333333
85,REQ-43730,Saxenda,SAX 062,"A patient with a family history of thyroid cancer, unknown what kind in her mother.  She has regular thyroid labs. It is normal. What else do I need to monitor and at what frequency?  Also, what is a patient has had a thyroidectomy with cancer. Is she a c",not accurate,"{'monitor', 'regular', 'cancer', 'thyroidectomy', 'thyroid cancer', 'thyroid'}","thyroid,thyroid neoplasms,mtc,men 2,calcitonin",Thyroid Neoplasms (SAX 018) (v1.0),SAX 018,",men 2,calcitonin,mtc,thyroid,thyroid neoplasms",10.0,"{'monitor', 'regular', 'cancer', 'thyroidectomy', 'thyroid cancer', 'thyroid'}","cancer,tumor,oncology,neoplasm,carcinoma,breast",Breast Neoplasms (SAX 010) (v7.0),SAX 010,",tumor,breast,cancer,neoplasm,oncology,carcinoma",9.0909090909,"{'monitor', 'regular', 'cancer', 'thyroidectomy', 'thyroid cancer', 'thyroid'}","pancreas,cancer,pancreatic,tumor,oncology,neoplasm,carcinoma",Pancreatic Cancer (SAX 015) (v7.0),SAX 015,",tumor,cancer,neoplasm,pancreas,pancreatic,oncology,carcinoma",8.3333333333
86,REQ-43731,Rybelsus,OSEM 043,What data is there for semaglutide use and patients with CKD? Rybelsus or Ozempic,not accurate,"{'data', 'rybelsus', 'ozempic', 'use', 'semaglutide'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",28.5714285714,"{'data', 'rybelsus', 'ozempic', 'use', 'semaglutide'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",25.0,"{'data', 'rybelsus', 'ozempic', 'use', 'semaglutide'}","ozempic,comparison,semaglutide injection,semaglutide sq,semaglutide sc,semaglutide subcutaneous,semaglutide comparison",vs Ozempic (OSEM 040) (v16.0),OSEM 040,",semaglutide subcutaneous,ozempic,semaglutide injection,semaglutide comparison,compare,semaglutide sc,semaglutide sq",9.0909090909
87,,Rybelsus,SEM 126,What data is there for semaglutide use and patients with CKD? Rybelsus or Ozempic,not accurate,"{'data', 'rybelsus', 'ozempic', 'use', 'semaglutide'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",28.5714285714,"{'data', 'rybelsus', 'ozempic', 'use', 'semaglutide'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",25.0,"{'data', 'rybelsus', 'ozempic', 'use', 'semaglutide'}","ozempic,comparison,semaglutide injection,semaglutide sq,semaglutide sc,semaglutide subcutaneous,semaglutide comparison",vs Ozempic (OSEM 040) (v16.0),OSEM 040,",semaglutide subcutaneous,ozempic,semaglutide injection,semaglutide comparison,compare,semaglutide sc,semaglutide sq",9.0909090909
88,REQ-43734,Rybelsus,OSEM 072,Provider would like additional information on Rybelsus and pancreatitis. Recommend sending Ryblesus MI Infographic on pancreatitis.,not accurate,"{'rybelsus', 'send', 'mi', 'information', 'pancreatitis'}","triglyceride,hypertriglyceridemia,pancreatitis",High Triglycerides and Pancreatitis (OSEM 079) (v5.0),OSEM 079,",hypertriglyceridemia,triglyceride,pancreatitis",14.2857142857,"{'rybelsus', 'send', 'mi', 'information', 'pancreatitis'}","safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,",ae,rybelsus,ozempic,safety",12.5,"{'rybelsus', 'send', 'mi', 'information', 'pancreatitis'}","cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,",ozempic,rybelsus,semglutide,cardiovascular,indication",11.1111111111
89,REQ-43735,Saxenda,SAX 080,HCP requested information on storage and stability for Saxenda.,accurate with one of docID,"{'stable', 'storage', 'hcp', 'information'}","summary,overview,information,monograph",Product Overview (SAX 025) (v7.0),SAX 025,",information,summary,overview,monograph",14.2857142857,"{'stable', 'storage', 'hcp', 'information'}","in-use,storage,stability,expiration,fridge,frozen,freeze,heat,hot,refrigerate,refrigeration,refrigerator,stable,store,temp,temperature,unopen,unopened,warm,room,cool,stored",Storage and Stability (SAX 080) (v4.0),SAX 080,",refrigerator,temp,hot,temperature,freeze,warm,room,frozen,unopen,stored,expiration,fridge,heat,store,stable,cool,storage,in-use",10.0,"{'stable', 'storage', 'hcp', 'information'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0
90,REQ-43737,Ozempic,SEM 016,Provider has pt who’s sister has medullary thyroid cancer and wants to know if she can give to her pt.,accurate with one of docID,"{'thyroid', 'medullary', 'cancer', 'thyroid cancer'}","neoplasms,cancer,neoplasm",Neoplasms  (SEM 134) (v7.0),SEM 134,",neoplasm,cancer",20.0,"{'thyroid', 'medullary', 'cancer', 'thyroid cancer'}","thyroid,neoplasms,carcinoma,cancer,thyroid cancer,ptc,papillary thyroid carcinoma,mtc,medullary thyroid carcinoma,men2,men 2,multiple endocrine neoplasia syndrome type 2,neoplasia,follicular thyroid cancer,ftc",Thyroid Neoplasms (SEM 016) (v10.0),SEM 016,",cancer,ptc,men 2,multiple endocrine neoplasia syndrome type 2,men2,neoplasm,mtc,ftc,neoplasia,thyroid cancer,medullary thyroid carcinoma,thyroid,follicular thyroid cancer,papillary thyroid carcinoma,carcinoma",18.75,"{'thyroid', 'medullary', 'cancer', 'thyroid cancer'}","thyroid cancer,hypothyroidism,hyperthyroidism,goiter,thyroid,nodules,thyroidectomy,ptc,papillary thyroid carcinoma,mtc,medullary thyroid carcinoma,men2,men2,multiple endocrine neoplasia syndrome type 2",Thyroid Conditions (SEM 012) (v5.0),SEM 012,",hypothyroidism,goiter,ptc,multiple endocrine neoplasia syndrome type 2,thyroidectomy,men2,nodules,hyperthyroidism,mtc,thyroid cancer,medullary thyroid carcinoma,thyroid,papillary thyroid carcinoma",13.3333333333
91,REQ-43742,Ozempic,SEM 008,Please send the MI letters SEM 007 (Antibodies) and SEM 008 (Allergic Reactions),accurate with one of docID,"{'send', 'mi', 'allergy', 'reaction', 'antibody'}","allergic,allergies,allergy,hypersensitivity,angioedema,anaphylactic,anaphylaxis,immunogenicity,reaction,reactions,skin,",Allergic Reactions (SEM 008) (v7.0),SEM 008,",immunogenic,hypersensitivity,anaphylaxis,angioedema,anaphylactic,allergy,reaction,skin",18.1818181818,"{'send', 'mi', 'allergy', 'reaction', 'antibody'}","antibody,antibodies,immunogenicity",Antibodies (SEM 007) (v8.0),SEM 007,",immunogenic,antibody",16.6666666667,"{'send', 'mi', 'allergy', 'reaction', 'antibody'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0
92,,Ozempic,SEM 007,Please send the MI letters SEM 007 (Antibodies) and SEM 008 (Allergic Reactions),accurate with one of docID,"{'send', 'mi', 'allergy', 'reaction', 'antibody'}","allergic,allergies,allergy,hypersensitivity,angioedema,anaphylactic,anaphylaxis,immunogenicity,reaction,reactions,skin,",Allergic Reactions (SEM 008) (v7.0),SEM 008,",immunogenic,hypersensitivity,anaphylaxis,angioedema,anaphylactic,allergy,reaction,skin",18.1818181818,"{'send', 'mi', 'allergy', 'reaction', 'antibody'}","antibody,antibodies,immunogenicity",Antibodies (SEM 007) (v8.0),SEM 007,",immunogenic,antibody",16.6666666667,"{'send', 'mi', 'allergy', 'reaction', 'antibody'}",excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,",excursion",0.0
93,REQ-43743,Rybelsus,OSEM 044,Please send the MI letter OSEM 044 (Allergic Reactions),accurate with one of docID,"{'reaction', 'send', 'mi', 'allergy'}","cv,cardiovascular,mace,heart attack,mi,stroke,death,indication",CV Indication (OSEM 093) (v9.0),OSEM 093,",stroke,mace,mi,cardiovascular,indication,heart attack,death",10.0,"{'reaction', 'send', 'mi', 'allergy'}","allergic,allergy,hypersensitivity,sensitivity,anaphylaxis,anaphylactic,urticaria,rash,immunogenic,immunogenicity",Allergic Reactions (OSEM 044) (v8.0),OSEM 044,",immunogenic,hypersensitivity,anaphylaxis,anaphylactic,allergy,urticaria,sensitivity,rash",9.0909090909,"{'reaction', 'send', 'mi', 'allergy'}","niosh,hazardous",NIOSH Classification (Sema) (SEM 300) (v6.0),SEM 300,",hazardous,niosh",0.0
94,REQ-43747,Ozempic,SEM 1000,What are the baseline study medications used in Sustain 6? What were the specific Diabetes and CV standards of care used in the study and the breakdown? What were the specific oral antidiabetic treatments used?,not accurate,"{'study', 'cardiovascular', 'oral', 'baseline', 'sustain', 'sustain 6', 'medications', 'medication', 'diabetes', 'antidiabetic'}","step,sustain,forte,diabetes,t2d",STEP 2 vs SUSTAIN FORTE (SEOB 057) (v1.0),SEOB 057,",step,forte,t2d,sustain,diabetes",15.3846153846,"{'study', 'cardiovascular', 'oral', 'baseline', 'sustain', 'sustain 6', 'medications', 'medication', 'diabetes', 'antidiabetic'}","cv,cardiovascular",SUSTAIN 6-CV Outcomes in Subgroup of Patients with CV Risk Factors (SEM 165) (v3.0),SEM 165,",cardiovascular",10.0,"{'study', 'cardiovascular', 'oral', 'baseline', 'sustain', 'sustain 6', 'medications', 'medication', 'diabetes', 'antidiabetic'}","cvot,glp-1,glp-1 ra,glp1,rewind,sustain 6,pioneer 6,excel,elixa,harmony,cv,outcomes,mace,leader",Overview of CVOTs  (GLP1 123) (v12.0),GLP1 123,",mace,cvot,glp-1 ra,cardiovascular,excel,sustain 6,outcomes,leader,rewind,harmony,glp-1,elixa,pioneer 6",9.5238095238
95,REQ-43748,Ozempic,SEM 109,Please send a copy of Sustain 9 study,accurate with one of docID,"{'study', '9', 'send', 'sustain', 'sustain 9'}","sustain,sglt-2,sglt2,add,sustain 9,sustain 9",Cover to SUSTAIN 9 (add-on SGLT-2i) (SEM 109) (v5.0),SEM 109,",sglt2,sustain,sglt-2,add,sustain 9",25.0,"{'study', '9', 'send', 'sustain', 'sustain 9'}","sustain,trulicity,dulaglutide",Cover to SUSTAIN 7 (vs dulaglutide) (SEM 107) (v5.0),SEM 107,",dulaglutide,sustain,trulicity",14.2857142857,"{'study', '9', 'send', 'sustain', 'sustain 9'}","sustain,monotherapy,naive,treatment-naive",Cover to SUSTAIN 1 (monotherapy)  (SEM 101) (v6.0),SEM 101,",naive,sustain,monotherapy,treatment-naive",12.5
96,REQ-43749,Ozempic,SEM 1000,What are the baseline study medications used in Sustain 6? What were the specific Diabetes and CV standards of care used in the study and the breakdown? What were the specific oral antidiabetic treatments used?,not accurate,"{'study', 'cardiovascular', 'oral', 'baseline', 'sustain', 'sustain 6', 'medications', 'medication', 'diabetes', 'antidiabetic'}","step,sustain,forte,diabetes,t2d",STEP 2 vs SUSTAIN FORTE (SEOB 057) (v1.0),SEOB 057,",step,forte,t2d,sustain,diabetes",15.3846153846,"{'study', 'cardiovascular', 'oral', 'baseline', 'sustain', 'sustain 6', 'medications', 'medication', 'diabetes', 'antidiabetic'}","cv,cardiovascular",SUSTAIN 6-CV Outcomes in Subgroup of Patients with CV Risk Factors (SEM 165) (v3.0),SEM 165,",cardiovascular",10.0,"{'study', 'cardiovascular', 'oral', 'baseline', 'sustain', 'sustain 6', 'medications', 'medication', 'diabetes', 'antidiabetic'}","cvot,glp-1,glp-1 ra,glp1,rewind,sustain 6,pioneer 6,excel,elixa,harmony,cv,outcomes,mace,leader",Overview of CVOTs  (GLP1 123) (v12.0),GLP1 123,",mace,cvot,glp-1 ra,cardiovascular,excel,sustain 6,outcomes,leader,rewind,harmony,glp-1,elixa,pioneer 6",9.5238095238
97,REQ-43750,Ozempic,SEM 109,Please send a copy of Sustain 9: Ozempic added on to SGLT2,accurate with one of docID,"{'9', 'ozempic', 'sglt2', 'send', 'sustain', 'sustain 9'}","sustain,sglt-2,sglt2,add,sustain 9,sustain 9",Cover to SUSTAIN 9 (add-on SGLT-2i) (SEM 109) (v5.0),SEM 109,",sglt2,sustain,sglt-2,add,sustain 9",37.5,"{'9', 'ozempic', 'sglt2', 'send', 'sustain', 'sustain 9'}","sustain,trulicity,dulaglutide",Cover to SUSTAIN 7 (vs dulaglutide) (SEM 107) (v5.0),SEM 107,",dulaglutide,sustain,trulicity",12.5,"{'9', 'ozempic', 'sglt2', 'send', 'sustain', 'sustain 9'}","sustain,monotherapy,naive,treatment-naive",Cover to SUSTAIN 1 (monotherapy)  (SEM 101) (v6.0),SEM 101,",naive,sustain,monotherapy,treatment-naive",11.1111111111
98,REQ-43758,General,GEN 087,Wanted more info on investigator sponsored studies and who to contact,not accurate,"{'study', 'investigator', 'contact'}","contact,reach",Unable to Reach (GEN 104) (v6.0),GEN 104,",reach,contact",25.0,"{'study', 'investigator', 'contact'}","trial,site,investigator,clinical trial site",Potential NNI Clinical Trial Investigator (GEN 032) (v5.0),GEN 032,",investigator,trial,site,clinical trial site",16.6666666667,"{'study', 'investigator', 'contact'}","product information,pi,package insert",PI Discussion (Verbal Response Only) (GEN 1001) (v2.0),GEN 1001,",package insert,product information,pi",0.0
